BioSpace News Archive

Vaxxas announced that the global charitable foundation, Wellcome, has made an award totaling US$3.67 million to conduct IND-enabling studies and a first-in-human clinical study for a potentially second generation typhoid vaccine delivered by Vaxxas’ proprietary high-density microarray patch platform technology.

Samsung Biologics, a global contract development and manufacturing organization, announced the appointments of Gail Ward as Executive Vice President and Head of the Quality Center, and Sojeong Lee as Vice President and Head of Regulatory Affairs.

SK bioscience announced that the company has entered into a collaboration agreement with Vaxxas, an Australian biotechnology company developing a unique vaccine patch platform technology, to develop a second-generation typhoid conjugate vaccine with support from Wellcome.

Medtronic announced the outcome of the U.S. Food & Drug Administration Circulatory System Devices Panel meeting to review data presented in support of the Medtronic Symplicity Spyral™ Renal Denervation System.

PeptiGrowth Inc and Orizuru Therapeutics, Inc have entered into a joint development agreement to create a novel synthetic peptide that will replace a recombinant growth factor used in the manufacturing of regenerative medicine product developed by OZTx.